The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative ...
Merck is buying Cidara Therapeutics for $9.2B, picking up an experimental flu therapy as it looks to broaden its pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback